



SOURCE: Acasti Pharma Inc.

Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston

- *Phase II Open Label Trial results for prescription drug candidate, CaPre[®] to be presented on July 26, 2014 at 12:30 p.m.*

Laval, Québec, CANADA – July 24, 2014 – Acasti Pharma Inc. (“**Acasti**” or the “**Corporation**”) (NASDAQ:ACST – TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19th World Congress on Heart Disease. Pierre Lemieux, PhD, Acasti’s Chief Operating Officer, will present CaPre[®] Phase II Open Label (COLT) trial results, previously announced in August 2013. A copy of the abstract will be available on Acasti’s website upon conclusion of the conference: acastipharma.com/en/investor-relations/events.

The COLT trial was a randomized open-label, dose ranging, multi-centre study designed to assess the safety and efficacy of CaPre[®] in mild-to-severe hypertriglyceridemic patients. CaPre[®] was found to be safe and effective in reducing triglyceride levels, with triglyceride lowering activity seen at all doses tested. As well, CaPre[®] had a positive impact on multiple lipoproteins, including high-density lipoprotein (HDL) and non-HDL, and no significant deleterious effect on low-density lipoprotein (LDL).

Acasti has recently completed its other Phase II trial, the double-blind, placebo-controlled (TRIFECTA) study. Top-line results for the TRIFECTA trial are expected by the end of September 2014, with full data coming out in the following quarter.

About Acasti Pharma Inc.

Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids (“PUFAs”), mainly eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre[®], currently Acasti’s only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA[®], a medical food and currently Acasti’s only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre[®].

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws, both of which we refer to as forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with

the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Except as required by law, Acasti disclaims any intention or obligation to update or revise any forward-looking statements.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Acasti in its public securities filings available at www.sedar.com and www.sec.gov/edgar.shtml, actual events may differ materially from current expectations. Except as required by law, Acasti disclaims any intention or obligation to update or revise any forward-looking statements.

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact:

André Godin
Interim President & CEO
Interim CFO Acasti
+1.450.687.2262
a.godin@neptunebiotech.com
acastipharma.com

John Ripplinger
Investor Relations
+1.450.687.2262
j.riplinger@acastipharma.com
acastipharma.com